Back in 1983, Congress set up a way of reimbursing items and services in hospitals that didn't take rare or ultra rare into account. Made sense at the time because 1983 was also the year we passed the Orphan Drug Act, trying to incentivize rare and ultra rare. It's time to update the way we pay hospitals so they aren't disadvantaged every time they treat a rare/ultra rare patient.
Recordati Rare Drug's comment letter urges adjustments to the methodology used to calculate and recalibrate Medicare Severity Diagnosis-Related Groups.
Agilis' comment letter on IPPS urges equitable payment for rare diseases.
Read comments from the National MPS Society on IPPS urging making access to treatment for patients with rare diseases a priority.
Read the Bellicum Pharmaceuticals comment on the Hospital Inpatient proposed rule.